A Phase 1, Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-gp Substrate Dabigatran Etexilate in Healthy Subjects
Kunta et al. • 2024 • AAPS 2024 Congress
Kunta et al. • 2024 • AAPS 2024 Congress
© 2024 Corcept Therapeutics, Incorporated